Genentech announced positive top-line results for its Phase 3 Archway study, which evaluated the first-of-its-kind Port Delivery System (PDS) with ranibizumab in neovascular or “wet” AMD. PDS is a permanent refillable eye implant, approximately the size of a grain of rice, which continuously delivers a customized formulation of ranibizumab. The study met its primary endpoint, and top-line results showed that PDS, when refilled every 6 months, achieved similar visual acuity outcomes to that of monthly ranibizumab injections.
Mynosys Cellular Devices, manufacturer of the ZEPTO Precision Cataract Surgery platform, has renamed itself Centricity Vision. The name change follows the recent appointment of Rob Thornhill as company CEO. New members of the executive team have also been announced, including Louis Bunn, chief financial officer; Todd Pinkney, vice president of marketing; Kevin Pratt, vice president of sales; Dan Glazerman, vice president of research, development and manufacturing; and Nealen Hartman, vice president of regulatory affairs and quality assurance.
Quest Diagnostics launched a new suite of “Return to Work” services, designed to help organizations access and act on COVID-19 laboratory insights to foster safer workplace environments for their employees. The Quest Diagnostics Return to Work services feature access to COVID-19 diagnostic and antibody testing and related capabilities, from event staffing to digital results reporting. For more information, visit www.QuestforHealth.com.
Kala Pharmaceuticals announced the FDA’s acceptance of a New Drug Application for its EYSUVIUS dry eye treatment. EYSUVIUS (loteprednol etabonate ophthalmic suspension) 0.25% is intended for the short-term treatment of the signs and symptoms of dry eye. The FDA set a PDUFA goal date of Oct. 30 for the completion of its NDA review.
Quick Notes is published weekly. Unless otherwise noted, the information presented is based on press releases. Find earlier editions here. To submit a press release to be considered for publication, click here.